Skip to content

GeoVax Labs, Inc.

GOVX· NasdaqCore metricsCIK 832489

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -15.34%
Market cap
$1.10M
544.45K shares
Filings
1,028
$0.00
Q3 2026−37.1% FY25 yoy
-$4.16M
Q3 2026N/M FY25 yoy
-$4.17M
Q3 2026N/M FY25 yoy
-$11.54M
Q3 2026derivedN/M FY25 yoy
-$3.04
FY 2021N/M FY21 yoy
$2.15M
Q3 2026−44.0% FY25 yoy
$1.10M
—
—
1.0×
-1503.85%
—

Twelve months to Sep 30, 2026 · derived

Price

$2.02+303.00%+$1.52past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$2.49MFY 2025
$3.95M0FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$2,489,145reported
FY 20242024-12-31$3,954,576reported
FY 20232023-12-31$0reported
FY 20222022-12-31$81,526reported
FY 20212021-12-31$385,501reported
FY 20202020-12-31$1,823,658reported
FY 20192019-12-31$1,175,896reported
FY 20182018-12-31$963,203reported
FY 20172017-12-31$1,075,270reported
FY 20162016-12-31$828,918reported

Segments

Products
Revenue by Products, FY2019 to FY2022FY2019NIH Grants · FY2019 · $983.68KResearch Agreements · FY2019 · $192.21KFY2020NIH Grants · FY2020 · $1.44MResearch Agreements · FY2020 · $385.19KFY2021NIH Grants · FY2021 · $385.50KFY2022NIH Grants · FY2022 · $81.53K
LineFY2022ShareChange
NIH Grants$81.53K100%−78.9%
Research Agreements———
Total$81.53K

From the 10-K filed Feb 29, 2024GOVX

Pharmaceutical preparations

GeoVax Labs, Inc. is the 199th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

GeoVax Labs, Inc. · CIK 832489 · Engraved from SEC EDGAR